NCT04494399 is a Phase 2 clinical trial of Interferon beta-1b in Covid19, sponsored by The University of Hong Kong.

Who is sponsoring NCT04494399?

NCT04494399 is sponsored by The University of Hong Kong.

What drugs are being tested in NCT04494399?

Interventions in NCT04494399: Interferon beta-1b, Ribavirin.

Is NCT04494399 still recruiting?

NCT04494399 is currently status unknown. Last updated 31 July 2020.

Last reviewed 2020-07-31 · How we verify

NCT04494399

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IFN Beta-1b and Ribavirin for Covid-19

Status unknown Phase 2 Last updated 31 July 2020

What this trial tests

Phase 2 trial testing Interferon beta-1b in Covid19 in 96 participants. Status unknown.

Timeline

29 July 2020

Primary endpoint
1 July 2022

1 August 2022

Quick facts

Lead sponsor	The University of Hong Kong
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	96
Start date	29 July 2020
Primary completion	1 July 2022
Estimated completion	1 August 2022
Sites	1 location across Hong Kong

Drugs / interventions tested

Interferon beta-1b (INTERFERON BETA-1B) — full drug profile →
Ribavirin — full drug profile →

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

The University of Hong Kong

Who can join

18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

As of 1 July 2020, more than 10 million people been confirmed to have infected by SARS-CoV-2, resulting in more than 500,000 deaths. No specific antiviral treatment for the SARS-CoV-2 is currently available, but existing medication could be repurposed. The investigators therefore propose to conduct an open-label randomized controlled trial on a short course of interferon β-1b and ribavirin combination treatment for patients hospitalized for COVID-19 infection.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Interferon beta-1b

Trials testing the same drug.

NCT04647695 — IFN-beta 1b and Remdesivir for COVID19 · Phase 2 · unknown
NCT04465695 — Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19 · Phase 2 · unknown

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other The University of Hong Kong trials

Trials by the same sponsor.

NCT05981430 — Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae · NA · not yet recruiting
NCT07478757 — Assessing the Effectiveness of Low-Dose Computed Tomography in Lung Cancer Screening for High-Risk Smokers: A Randomized · NA · not yet recruiting
NCT07448649 — Chatbot-Assisted Advance Care Planning Education for Family Members · NA · not yet recruiting
NCT07484932 — TRTRM (ACTTOP) -Guided Dosing Strategy in Older Patients With Cancer · NA · not yet recruiting
NCT07531589 — BrainLive Connect: Non-professional Delivered CST for People Living With Dementia · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04494399 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Hong Kong
Last refreshed: 31 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04494399.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing